Asked about the mid-term upside drivers for TriLink, particularly regarding commercial programs and biotech funding.

Management highlighted strong uptake in the discovery world leading to more GMP opportunities. Commercialization is expected around 2028-2029. Near-term TriLink growth is high single-digit, moving to low double-digit as clinical programs convert to commercial supply, with ModTail as a potential inflection point. “ModTail is a lever layered on top of that, that can really create like an inflection point for the business.”

Inquired about MockV growth, potential regulatory guidance, and its contribution to Cygnus growth.

Management stated MockV is a small but growing base contributing to Cygnus, but they do not disclose specific growth rates. It's too early for regulatory intel. “We don't really give the MockV growth rates, but it's a small base and is continuing to grow and contribute to Cygnus' growth profile.”

Asked about the performance of the new online strategy relative to expectations and its ramp.

Management stated e-commerce is performing much better than anticipated, driving significant orders and new customer acquisitions, particularly in the discovery world. “the short answer is it's going much better than we even had anticipated. The adoption is incredible.”

MRVI

Maravai LifeSciences (MRVI) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 6, 2026

Source: earnings call transcript

Executive summary

Maravai LifeSciences Q2 FY26 — Strong Execution Drives Profitability and Balance Sheet Improvement

Maravai LifeSciences delivered a strong second quarter, marked by significant profitability improvements and a strengthened balance sheet. The company's strategic focus on innovation, commercial execution, and operational excellence drove robust growth in high-margin mRNA segments, particularly GMP consumables and discovery. While full-year revenue guidance was maintained due to the inherent lumpiness of large orders, management expressed confidence in the underlying business momentum and long-term growth trajectory as customer programs advance.

Highlights

Revenue grew 9% year-over-year to $51.4 million, driven by strong demand for GMP consumables and discovery mRNA.
Adjusted gross margin expanded over 1,600 basis points year-over-year to 58.9%.
Adjusted EBITDA improved by $19.1 million year-over-year to $8.7 million, exceeding expectations.
Debt refinanced, reducing borrowings to approximately $150 million and extending maturities to 2032.
TriLink's GMP consumables grew 55% year-over-year, with no COVID-related revenue.
Added 67 new customers in Q2, a record for new customer acquisitions, largely driven by e-commerce.

Concerns

CDMO business was down year-over-year, in line with expectations due to timing of customer programs.
Revenue guidance for FY26 maintained at $205 million to $215 million, reflecting prudence due to lumpiness of large orders and CDMO projects.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Revenue	$205 million to $215 million high materiality	FY26	High
Full-year 2026 TriLink Revenue Growth	high teens medium materiality	FY26	High
Full-year 2026 Cygnus Revenue Growth	low to mid-single-digit growth medium materiality	FY26	High
Full-year 2026 Adjusted EBITDA	$33 million to $35 million high materiality	FY26	High
Full-year 2026 Adjusted Gross Margin Improvement	greater than 1,400 basis points medium materiality	FY26	High
GMP ModTail Orders	expected in 2027 medium materiality	FY27	High
Commercial Program Launches (non-COVID)	expected to begin around 2028 and 2029 high materiality	FY28-FY29	Medium
TriLink mRNA Business Long-term Growth	high single-digit to low double-digit rates high materiality	long-term	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
TriLink Driven by strong demand for GMP consumables and continued strength in discovery mRNA. CDMO was down year-over-year due to timing of customer programs. Specialty chemistry was steady. Benefited from high-margin GMP product mix and improved operating leverage. mRNA revenue growth: 17% YoY (Discovery mRNA)GMP consumables growth: 55% YoYCDMO revenue: <5% of expected 2026 revenueSpecialty chemistry revenue: >20% of expected 2026 revenueAdjusted EBITDA improvement: $14.2 million YoY	$34.4 million	12%	—	$7 million adjusted EBITDA
Cygnus Delivered another solid quarter, marking its fifth consecutive quarter of growth. Saw steady demand for HCP and ELISA kits and strength in China due to distributor ordering timing. HCP and ELISA kits demand: steadyChina revenue strength: due to distributor ordering timing	$17 million	3%	—	$11.4 million adjusted EBITDA

Product announcements

Product	Type	Timeline
GMP-grade enzyme portfolio	launch	Q2 FY26
GMP-grade ModTail	launch	later this year (H2 FY26)
Residual Prism A Mix-N-Go kit	launch	Q2 FY26

Risks & headwinds

Variability in timing of large program-driven orders Quarter-to-quarter

Individual orders can be large (multi-million dollar type) and their timing can vary meaningfully quarter-to-quarter.

Mitigation:Prudent revenue guidance; practice not to assume orders until confirmed.

Project-based and variable nature of CDMO business Quarter-to-quarter

CDMO was down year-over-year and in line with expectations based on the timing of customer programs.

Mitigation:Acknowledged as inherent to the business; managed through selective customer engagement.

What to watch in Q3 FY26

GMP Customer Conversions

next quarter (Q3 FY26) and Q4 FY26

Current 6 YTD (4 in Q2)

Target 9 for FY26

Why it matters

Indicates progress of customer programs from discovery to clinical development, a key driver of future revenue.

So we're at 6 now. We added 4 in the second quarter. And so yes, we see the 9 for -- the 3 remainder for the year that should be changed.

Find out whether MRVI delivers this. Inve re-checks your case every morning.

Q&A highlights

Inquired about the prudence behind maintaining revenue guidance despite strong H1, noting the implied step-down in H2, and asked about ModTail/Enzyme contributions.

Management confirmed the prudence is due to the lumpiness of large CDMO and GMP orders, which are program-driven and not assumed until confirmed. Q3 is seasonally lower. GMP ModTail orders are expected in 2027, while the first enzyme order has shipped.

“Our practice is not to assume those orders until we can see them.”

asked by Matthew Stanton · answered by Rajesh Asarpota

2 min read 5 chapters

Detailed narrative

Strategic Priorities and Execution

Maravai continued to execute against its three strategic priorities: innovation, commercial execution, and operational excellence. Innovation efforts included the launch of a new GMP-grade enzyme portfolio and a new residual Prism A Mix-N-Go kit, alongside expanding mass spec analytical services.

Commercial momentum was strong, evidenced by 67 new customer acquisitions in Q2 and record e-commerce revenue. Operational excellence was driven by completed restructuring actions and debt refinancing, fundamentally resetting the cost structure and building an operating model designed for scale.

TriLink Business Model Breakdown

To provide greater investor visibility, TriLink's business is now viewed through three distinct market categories: mRNA, CDMO, and specialty chemistry. mRNA is the largest and most strategic, spanning discovery (17% YoY growth in Q2), GMP consumables (55% YoY growth in Q2), and future commercial programs (expected 2028-2029).

CDMO, representing less than 5% of FY26 revenue, serves strategic cell and gene therapy customers. Specialty chemistry, over 20% of FY26 revenue, is a stable research tools business with attractive profitability.

Balance Sheet and Financial Flexibility

The company significantly strengthened its balance sheet by refinancing debt in June, reducing borrowings to approximately $150 million and extending maturities to 2032. This action, combined with improving profitability, positions Maravai with enhanced liquidity and financial flexibility, supporting future growth initiatives and long-term stability.

E-commerce Platform Driving Customer Growth

Maravai's e-commerce platform delivered record quarterly revenue and was a primary driver for the record 67 new customer acquisitions in Q2. This digital strategy is improving ordering automation, data-driven customer engagement, and predictive analytics, particularly in the smaller discovery research segment, contributing to a strong rebound in basic research markets.

Advancement of GMP Customer Programs

Maravai reported adding 4 new GMP customers in Q2, bringing the total to 6 conversions year-to-date against an annual target of 9. This progress highlights the successful advancement of customer programs from discovery into clinical development, leveraging TriLink's infrastructure and expanding product offerings like GMP CleanCap and soon GMP ModTail.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.